

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form 425

JAZZ PHARMACEUTICALS INC

Form 425

November 15, 2011

Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934

Filing by: Jazz Pharmaceuticals, Inc.

Subject Company: Jazz Pharmaceuticals, Inc.

SEC File No. of Jazz Pharmaceuticals, Inc.:

001-33500

Registration No. 333-177528

The following includes a slide presentation relating to the proposed transactions described therein that was first used on November 15, 2011 at the 8th Annual Lazard Capital Markets Healthcare Conference.

Bruce Cozadd
Chairman and CEO
November 15, 2011
8
th
Annual Lazard Capital Markets
Healthcare Conference

Forward-Looking Statements

2

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

dependence

on

sales

of

Xyrem
®
and
Luvox
CR
®
products
and
its
ability
to
increase
sales
of
its
Xyrem;

This presentation contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' growth potential and future financial performance, including 2011 financial guidance, and statements related to the anticipated consummation of the business combination transaction between Jazz Pharmaceuticals and Azur Pharma Public Limited Company (formerly Azur Pharma Limited), including the timing and benefits thereof. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; regulatory obligations and oversight; Jazz Pharmaceuticals' cash flow; and Jazz Pharmaceuticals' ability to complete the transaction with Azur Pharma on the proposed terms and schedule and achieve the anticipated benefits of the transaction. These and those other applicable risks are described in more detail under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission (SEC) filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and definitive proxy statement related to the Azur Pharma transaction. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in its expectations.

3

Additional Information

Additional Information and Where to Find It

In connection with the proposed transaction between Jazz Pharmaceuticals and Azur Pharma, the companies have filed with the SEC, including the filing by Jazz Pharmaceuticals of a definitive proxy statement relating to the proposed transaction and related matters and the filing by Azur Pharma of a registration statement on Form S-4 that includes the definitive proxy statement/prospectus relating to the proposed transaction and related matters. The definitive proxy statement/prospectus has been mailed to Jazz Pharmaceuticals

connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED DEFINITIVE PROXY STATEMENT/PROSPECTUS BECAUSE THE INFORMATION ABOUT JAZZ PHARMACEUTICALS, AZUR PHARMA, THE PROPOSED TRANSACTION AND RELATIONSHIP INFORMATION AND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THESE DOCUMENTS AND OTHER RELATED DOCUMENTS FILED WITH THE SEC AT THE SEC'S WEBSITE www.sec.gov, OR BY DIRECTING A REQUEST TO JAZZ PHARMACEUTICALS' INVESTOR RELATIONS DEPARTMENT AT JAZZ PHARMACEUTICALS, INC., INVESTOR RELATIONS, 3180 PORTER DRIVE, PALO ALTO, CALIFORNIA 94304, TO JAZZ PHARMACEUTICALS' INVESTOR RELATIONS DEPARTMENT AT 650-496-4400, OR BY E-MAIL AT investorinfo@jazzpharma.com. INVESTORS AND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THE DOCUMENTS FILED WITH THE SEC ON JAZZ PHARMACEUTICALS' WEBSITE AT www.jazzpharmaceuticals.com UNDER THE HEADING "INVESTORS" AND THEN UNDER THE HEADING "SECURITIES."

Jazz Pharmaceuticals and its directors and executive officers and Azur Pharma and its directors and executive officers are participants in the solicitation of proxies from the stockholders of Jazz Pharmaceuticals in connection with the proposed transaction. The information regarding the special interests of these directors and executive officers in the proposed transaction is included in the proxy statement described above. Additional information regarding the directors and executive officers of Jazz Pharmaceuticals is also included in Jazz Pharmaceuticals' proxy statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2011. These documents are available free of charge at the SEC's web site and from Investor Relations at Jazz Pharmaceuticals as described above.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. For full prescribing information refer to product websites.

Building Shareholder Value by Focusing on Patient Needs
Jazz Pharmaceuticals
mission is to improve
patients
lives by identifying, developing and
commercializing valuable pharmaceutical
products in focused therapeutic areas

5
Strategy to Build Shareholder Value
Grow Xyrem sales in
current indications
Increased focus on
achieving full potential
1

Maintain entrepreneurial, ownership culture at the company

4

Make disciplined resource allocation decisions

2

3

Acquire additional
marketed or close to
approval products

Leverage our expertise
and infrastructure

Pursue lower risk
development of
specialty products

Invest percentage
of sales longer-term

Current Business Overview

\$39
\$54
\$97
\$230-235
1
2010
2009

2008

2007

2011G

\$143

\$0

\$25

\$50

\$75

\$100

\$175

\$200

\$125

\$150

\$225

\$250

Xyrem -

Strong Sales Growth

8%

7

1.

Based on guidance provided on November 1, 2011. The company is not updating the prior guidance and actual results may dif

Xyrem is a Standard of Care in Narcolepsy

Only FDA-approved product for both cataplexy and excessive daytime sleepiness in patients with narcolepsy

Marketed in U.S. since 2002

Marketed in major European countries by
UCB and in Canada by Valeant

Currently marketed in U.S. by 110-person specialty sales force

Over 9,000 patients on therapy, usually in conjunction with stimulant therapy

Distributed
under
proprietary
Xyrem
Success
Program
®
8

The Burden of Narcolepsy

Affects

1

in

2000

in

US

1

multiple
sclerosis
and
Parkinson's
disease

2

>
cystic
fibrosis

3

Although narcolepsy is thought to affect between
125,000 and 200,000 Americans, only about
50,000
are
diagnosed

4

Key symptoms can be debilitating

Cataplexy occurs in 60%-100% of patients

100% experience excessive daytime sleepiness

1.

National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm

2.

Narcolepsy Sleep Foundation. www.sleepfoundation.org/article/sleep-related-problems/narcolepsy-and-sleep. Accessed March

3.

Zemanick et al. J Cyst Fibros. 2010;9:1-16.

4.

American Sleep Association. <http://www.sleepassociation.org/index.php?p=aboutnarcolepsy>. Accessed March 17, 2011.

9

2
-40
-30
-20
-10
0

Xyrem has Demonstrated Effect
on Two Key Symptoms of Narcolepsy

XYREM

6 g/night

(n=58)

XYREM

9 g/night

(n=47)

Placebo

(n=59)

16%

*

37%

*

3%

Improvement in Epworth

Sleepiness Scale

Week 2

Week 4

Baseline

Reduction in Weekly

Cataplexy Attacks

-28%

-49%*

-69%+

10

-80

-60

-40

-20

0

Placebo (n=33)

XYREM 6 g/night (n=31)

XYREM 9 g/night (n=33)

*p<0.001 vs placebo

*p<0.05 vs placebo

+p<0.005 vs placebo

1

Most Common Adverse Events in
Controlled Studies of Xyrem

Adverse Event

1

% of Patients (N=655)

Placebo

Xyrem

Nausea

4

19

Dizziness

4

18

Headache

15

18

Vomiting

1

8

Somnolence

4

6

Urinary incontinence

4

<1

6

Nasopharyngitis

5

6

Label includes boxed warning that sodium oxybate is a central nervous system depressant with abuse potential and should not be used with alcohol or other CNS depressants. See complete boxed warning at end of presentation.

11

2

3

1. Occurring

in

5%

of

XYREM

patients

and

more

frequently

than

with

placebo.

2.

Data

on

file,

Jazz

Pharmaceuticals,

Inc.

3.

XYREM

(sodium

oxybate)

PI.

4.

Generally

nocturnal

enuresis.

Update on FDA Form 483 and Related Warning Letter

Fully committed to accurate and timely adverse event (AE) reporting

After receipt of FDA Form 483 in May, immediate actions initiated to improve AE reporting procedures:

Implemented additional procedures at central pharmacy

Strengthened AE collection and reporting systems, including revised SOPs

Improved training and auditing programs

Timely response to October FDA warning letter submitted

Ongoing oversight strengthened to ensure robust safety reporting systems

12

Strong Sodium Oxybate Patent Coverage

* Listed in FDA Orange Book

13

Number

Issue Date

Expiration Date

Distribution system patent*

7,765,106
7/27/2010
6/16/2024
Distribution system patent*
7,765,107
7/27/2010
6/16/2024
Distribution system patent
7,797,171
9/14/2010
6/16/2024
Distribution system patent*
7,668,730
2/23/2010
6/16/2024
Distribution system patent*
7,895,059
2/23/2011
12/17/2022
Formulation patent*
6,780,889
8/24/1999
7/4/2020
Formulation patent*
7,262,219
8/28/2007
7/4/2020
Process patent
6,472,431
10/29/1999
12/22/2019
Method of use patent*
7,851,506
12/14/2010
12/22/2019

Overview of Manufacturing and Distribution

DEA drug quota needed to manufacture controlled Schedule I
API

Exclusive relationships with API supplier and finished goods
manufacturer:

Siegfried approved by FDA for API supply

Unique proprietary distribution system uses exclusive single pharmacy

Risk management program and unique product attributes require high touch capabilities

14

Current Xyrem Patient Coverage Distribution*

Approximately 90% of insured patients
have access

Relatively low rates of required prior
authorizations

Low monthly out-of-pocket (OOP)
expenses

Over 70% of patients have monthly
OOP of
\$50
78%
8%
4%
1%
9%

* Company data and MediMedia Formulary Compass: Sep/Oct 2011.

Commercial
Medicaid
Medicare Part D
Patient
Assistance
Program
Cash
15

16

New narcolepsy physician targets

Xyrem Success Program education

Patient services

-

Nursing program

-

Xyrem Patient Connection

-

Patient assistance programs

Increased Marketing Investment

Xyrem Growth Initiatives

Improve Market Penetration Over Time

Current Patients >9,000

Approximately 18% of 50K Diagnosed Narcolepsy Patients

17

1. National Institute of Mental Health. <http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america>. 2003;160:1-10. 2. B, et al. Am J Psychiatry. 2001;158:1904-1910. 4. Grabill K et al..Assessment of obsessive-compulsive disorder: a review.J A

et al. Am J Health Syst Pharm. 2000;57:1972-1978.

Luvox CR

®

-

Important Treatment Option for OCD

Indicated for obsessive compulsive
disorder (OCD)

OCD affects ~ 2.2 million Americans

1,2

Often underdiagnosed

3,4

Difficult to differentiate from comorbidities

5

Only 43% of adults newly diagnosed with OCD received adequate treatment in the
year after their first visit for OCD

6

Label includes boxed warning regarding suicidality and antidepressant drugs.

See complete boxed warning at end of presentation.

Luvox CR
Continued Sales Growth
\$30
\$6
\$31-33
1
2009

2008
2011G
18
\$0
\$5
\$10
\$15
\$20
\$25
2010
2
\$18
\$35
\$40
\$27

1.
Based on guidance provided on November 1, 2011. The company is not updating the prior guidance and actual results may differ.

2.
Includes \$2 million of revenue recorded as a result of a change in the timing of when Luvox CR revenue is recognized. The company

19

2011 Guidance Reflects High Operating Leverage

1.

Based on guidance provided on November 1, 2011. The company is not updating the prior guidance and actual results may differ.

2.

Includes Azur transaction related expenses of \$10-11 million.

3.

Adjusted
net
income
and
adjusted
EPS
are
non-GAAP
financial
measures
that
exclude
certain
items
from
GAAP
net
income
and
GAAP
EPS.

A
reconciliation
of
adjusted
net
income to

GAAP net income and the related per share amounts is in a table included with this presentation.

2010-

A

2011-

G

1

Total Product Sales

\$170M

\$261

268M

Xyrem

\$143M

\$230 -

235M

Luvox CR

\$27M

\$31 -

33M

SG&A and R&D Combined

2

\$95M

\$114

118M

GAAP Net Income
\$33M
\$128
131M
Adjusted Net Income
3
\$61M
\$160
163M
GAAP EPS
\$0.83
\$2.76
\$2.81
Adjusted EPS
3
\$1.55
\$3.45
\$3.50

Strategic Transaction with
Azur Pharma

21

Strategic Benefits

Diversified portfolio of CNS and
women's health products

Increased scale and platform

for growth

Resources to invest in future
pipeline and strong franchise
management opportunities

Stronger, enhanced
management team
Projected Financial Benefits

Accretive transaction
1

Revenues >\$475M
and cash flow >\$200M in
first 12 months

Strong balance sheet
with no debt

Lower combined tax rate
1

Accretion for Jazz Pharmaceuticals shareholders is on a fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financial
Compelling Strategic and Financial Benefits

Jazz
Pharmaceuticals plc
Ireland

Azur Pharma
Compelling Fit with Jazz Pharmaceuticals
22
CNS
Women's
Health
Net Sales (Millions)

Strong commercial focus and expertise
in CNS and women's health

Approximately 170 employees:

105 people in 3 US sales forces
across pain, psychiatry and
women's health

16 person medical affairs team

50 people in home office
(18 Dublin; 32 Philadelphia)

Pipeline of line extensions for clozapine
franchise

1.
Based on estimate provided on September 19, 2011. The estimate is not being updated.

Total Net

Sales

Estimate

\$5

\$24

\$57

\$67

\$83

\$95-100

1

Prialt -
for Chronic Pain

2010 net sales of \$20M (marketed by Azur since May 2010)

Only
non-opioid

intrathecal
(IT)
analgesic
for
severe
chronic
pain
1

Compelling growth opportunity with similar characteristics to Xyrem:

Requires high touch sales capability with heavy clinical emphasis

Currently used in less than 3% of available pain market pumps (approximately 1500)

Limited competitive threats and multiple years of patent and other protection

European rights licensed to Eisai; Azur retains ROW rights

23

1. See full prescribing information on website

FazaClo
for Treatment Resistant Schizophrenia

2010 net sales of \$37M

Orally disintegrating clozapine tablets approved for management of treatment resistant schizophrenia

1

Approximately 10% prescription share despite largely generic clozapine market

FazaClo High Dose (HD) launched September 2010

More than 27% switched from Low Dose (LD) as of 3Q11

Dosing flexibility and lower pill burden

Generics

filed

to

FazaClo

settlement

with

Teva

with

potential

launch

of

lower

dosage

product in 2Q12 and HD in 2015

Additional clozapine line extensions in development

24

1. See full prescribing information on website

25

Diversified
and
balanced
set
of

six
products
1
with 2010 net sales of \$27M

Significant
growth
opportunity
driven
by
Elestrin
1
, a topical gel ERT therapy

Patents through 2022

Revamped Elestrin promotion model in 2010 leveraging ~ 50 sales representatives

0%
20%
40%
60%
80%
100%
2009
2010
2011E

Women's Health Products -
Targeting a Growing Market

Elestrin

Other Women's Health

Net Sales Contribution

1. See full prescribing information on website

26

2011 Estimated Net Sales

Stand Alone Jazz Pharmaceuticals, Inc.

Pro forma Jazz Pharmaceuticals plc

A Growing, Diversified Product Portfolio

Luvox CR

13%

Xyrem 87%

Xyrem 63%

Luvox CR

9%

Prialt 6%

Women's

Health 10%

Other CNS

1%

FazaClo LD

8%

FazaClo HD

3%

27

Transaction Closing on Track
SEC filings and
stockholder meeting
Transaction expected
to close January 2012
Transaction subject

to customary closing
conditions and
regulatory approvals

Azur approval of other
necessary actions required

US antitrust clearance
pending

Transaction taxable to Jazz
Pharmaceuticals, Inc.
stockholders

Jazz Pharmaceuticals plc shares
to be traded on Nasdaq under
JAZZ

Azur Pharma S-4 declared
effective

Proxy statement/prospectus
mailed to Jazz Pharmaceuticals,
Inc. stockholders in November

Jazz Pharmaceuticals, Inc.
stockholder meeting on
December 12, 2011

28

Strategic Benefits

Diversified portfolio of CNS and
women's health products

Increased scale and platform

for growth

Resources to invest in future
pipeline and strong franchise
management opportunities

Stronger, enhanced
management team
Projected Financial Benefits

Accretive transaction
1

Revenues >\$475M
and cash flow >\$200M in
first 12 months

Strong balance sheet
with no debt

Lower combined tax rate
1

Accretion for Jazz Pharmaceuticals shareholders is on a fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financial
Compelling Strategic and Financial Benefits

Jazz
Pharmaceuticals plc
Ireland

30

2010

Reconciliation of GAAP Net Income and EPS to Adjusted
Net Income and EPS in Financial Results and Guidance

(In millions, except per share amounts)

GAAP net income

Add:

Intangible asset amortization

Stock-based compensation expense

Non-cash interest expense and extinguishment of debt

Azur Pharma transaction related costs

Deduct:

Contract revenues

GAAP net income per diluted share (EPS)

Adjusted net income per diluted share (EPS)

Shares used in computing GAAP and adjusted net
income per diluted share amounts

Adjusted net income

Luvox CR revenue recognition timing change

(1)

\$128-131M

7

13

2

\$160-163

\$2.76-2.81

\$3.45-3.50

46-47

10-11

(1)

\$33

8

8

14

\$61

\$0.83

\$1.55

39

(1)

1.

Based on guidance provided on November 1, 2011. The company is not updating the prior guidance and actual results may differ.

-

-

2010

2011G

1

31

Xyrem

(sodium oxybate)

Boxed Warning

Sodium oxybate is GHB, a known drug of abuse. Abuse has been associated with some important central nervous system (CNS)

adverse

events
(including
death).
Even
at
recommended
doses,
use
has
been
associated
with
confusion,
depression
and
other
neuropsychiatric
events.

Reports
of
respiratory
depression
occurred
in
clinical
trials.

Almost
all
of
the
patients
who
received sodium oxybate during clinical trials were receiving CNS stimulants.

Important CNS adverse events associated with abuse of GHB include seizure, respiratory depression and profound decreases in level of consciousness, with instances of coma and death.

For
events
that
occurred
outside
of

clinical
trials,
in
people
taking
GHB
for
recreational
purposes,
the
circumstances
surrounding
the
events
are
often
unclear
(e.g.,
dose
of
GHB
taken,
the
nature and amount of alcohol or any concomitant drugs).

Xyrem
is
available
through
the
Xyrem
Success
Program,
using
a
centralized
pharmacy
1-866-XYREM88
®
(1-866-997-3688).
The
Success
Program
provides
educational
materials
to
the
prescriber
and
the

patient
explaining
the
risks
and
proper
use
of

sodium oxybate, and the required prescription form. Once it is documented that the patient has read and/or understood the materials, the drug will be shipped to the patient. The Xyrem Success Program also recommends patient follow-up every 3 months. Physicians are expected to report all serious adverse events to the manufacturer. (See WARNINGS).

XYREM (sodium oxybate) PI

!WARNING:

Central nervous system depressant with abuse potential.

Should not be used with alcohol or other CNS depressants.

Luvox CR
(fluvoxamine maleate)

Boxed Warning

LUVOX CR (fluvoxamine maleate) PI

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term

studies of major depressive disorder (MDD) and other psychiatric disorders.

Anyone considering the use of LUVOX CR® (fluvoxamine maleate)

Extended-Release Capsules or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.

Depression

and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. LUVOX CR Capsules are not approved for use in pediatric patients.

(See WARNINGS:

Clinical Worsening and Suicide Risk,

PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)

Prialt

(ziconotide intrathecal infusion)

Boxed Warning

Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Patients with a pre-existing history of psychosis should not be treated with PRIALT. All patients should be monitored frequently

for
evidence
of
cognitive
impairment,
hallucinations,

or
changes
in

mood or consciousness. PRIALT therapy can be interrupted or discontinued abruptly without evidence of withdrawal effects in the event of serious neurological or psychiatric signs or symptoms

Prialt (ziconotide intrathecal infusion) PI

WARNING:

FazaClo
(clozapine)

Boxed Warning

1. AGRANULOCYTOSIS

BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF SEVERELY ILL PATIENTS WITH SCHIZOPHRENIA WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE TO ADEQUATE COURSES OF STANDARD

ANTIPSYCHOTIC DRUG TREATMENT, OR (2) FOR REDUCING THE RISK OF RECURRENT SUICIDAL BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER WHO ARE JUDGED TO BE AT RISK OF REEXPERIENCING SUICIDAL BEHAVIOR. PATIENTS BEING TREATED WITH CLOZAPINE MUST HAVE A BASE

WHITE

BLOOD

CELL

(WBC)

COUNT

AND

ABSOLUTE

NEUTROPHIL

COUNT

(ANC)

BEFORE

INITIATION

OF

TREATMENT

AS WELL AS REGULAR WBC COUNTS AND ANC_s DURING TREATMENT AND FOR AT LEAST 4 WEEKS AFTER DISCONTINUATION OF TREATMENT. (SEE WARNINGS.) CLOZAPINE IS AVAILABLE ONLY THROUGH A DISTRIBUTION SYSTEM THAT ENSURES MONITORING OF WBC COUNTS AND ANC_s ACCORDING TO THE SCHEDULE

DESCRIBED

BELOW

PRIOR

TO

DELIVERY

OF

THE

NEXT

SUPPLY

OF

MEDICATION.

(SEE

WARNINGS.)

2. SEIZURES

SEIZURES HAVE BEEN ASSOCIATED WITH THE USE OF CLOZAPINE. DOSE APPEARS TO BE AN IMPORTANT PREDICTOR OF SEIZURE, WITH A GREATER LIKELIHOOD AT HIGHER CLOZAPINE DOSES. CAUTION SHOULD BE USED WHEN ADMINISTERING CLOZAPINE TO PATIENTS HAVING A HISTORY OF SEIZURES OR OTHER PREDISPOSING FACTORS. PATIENTS SHOULD BE ADVISED NOT TO ENGAGE IN ANY ACTIVITY WHERE SUDDEN LOSS OF CONSCIOUSNESS COULD CAUSE SERIOUS RISK TO THEMSELVES OR OTHERS. (SEE WARNINGS.)

3. MYOCARDITIS

ANALYSES OF POSTMARKETING SAFETY DATABASES SUGGEST THAT THAT CLOZAPINE IS ASSOCIATED WITH AN INCREASED RISK OF FATAL MYOCARDITIS, ESPECIALLY DURING, BUT NOT LIMITED TO, THE FIRST

MONTH

OF

THERAPY.

IN

PATIENTS

IN

WHOM

MYOCARDITIS
IS
SUSPECTED,
CLOZAPINE
TREATMENT
SHOULD
BE
PROMPTLY DISCONTINUED. (SEE WARNINGS.)
FazaClo (clozapine) PI
WARNING:

FazaClo
(clozapine)

Boxed Warning -
continued

4. OTHER ADVERSE CARDIOVASCULAR AND RESPIRATORY EFFECTS
ORTHOSTATIC
HYPOTENSION,

WITH
OR
WITHOUT
SYNCOPE,
CAN
OCCUR
WITH
CLOZAPINE
TREATMENT.
RARELY,
COLLAPSE CAN BE PROFOUND AND BE ACCOMPANIED BY RESPIRATORY AND/OR CARDIAC ARREST.
ORTHOSTATIC HYPOTENSION IS MORE LIKELY TO OCCUR DURING INITIAL TITRATION IN ASSOCIATION WITH
DOSE
ESCALATION.
IN
PATIENTS
WHO
HAVE
HAD
EVEN
A
BRIEF
INTERVAL
OFF
CLOZAPINE
(ie,
2
OR
MORE
DAYS
SINCE THE LAST DOSE) TREATMENT SHOULD BE STARTED WITH 12.5 MG ONCE OR TWICE DAILY. (SEE WARNINGS,
AND DOSAGE AND ADMINISTRATION.) SINCE COLLAPSE, RESPIRATORY ARREST, AND CARDIAC ARREST DURING
INITIAL TREATMENT HAS OCCURRED IN PATIENTS WHO WERE BEING ADMINISTERED BENZODIAZEPINES OR
OTHER PSYCHOTROPIC DRUGS, CAUTION IS ADVISED WHEN CLOZAPINE IS INITIATED IN PATIENTS TAKING
BENZODIAZEPINE OR ANY OTHER PSYCHOTROPIC DRUG. (SEE WARNINGS.)
5.
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT
INCREASED RISK OF DEATH. ANALYSES OF SEVENTEEN PLACEBO-CONTROLLED TRIALS (MODAL DURATION OF 12
WEEKS),
LARGELY
IN
PATIENTS
TAKING
ATYPICAL
ANTIPSYCHOTIC
DRUGS,
REVEALED
A
RISK

OF
DEATH
IN
DRUG-TREATED PATIENTS OF BETWEEN 1.6 TO 1.7 TIMES THE RISK OF DEATH IN PLACEBO-TREATED PATIENTS
OVER THE COURSE OF A TYPICAL 10-WEEK CONTROLLED TRIAL, THE RATE OF DEATH IN DRUG-TREATED
PATIENTS
WAS
ABOUT
4.5%,
COMPARED
TO
A
RATE
OF
ABOUT
2.6%
IN
THE
PLACEBO
GROUP.
ALTHOUGH
THE
CAUSES OF DEATH WERE VARIED, MOST OF THE DEATHS APPEARED TO BE EITHER CARDIOVASCULAR (eg,
FAILURE,
SUDDEN
DEATH)
OR
INFECTIOUS
(eg,
PNEUMONIA)
IN
NATURE.
OBSERVATIONAL
STUDIES
SUGGEST
THAT, SIMILAR TO ATYPICAL ANTIPSYCHOTIC DRUGS, TREATMENT WITH CONVENTIONAL ANTIPSYCHOTIC
MAY INCREASE MORTALITY. THE EXTENT TO WHICH THE FINDINGS OF INCREASED MORTALITY IN
OBSERVATIONAL STUDIES MAY BE ATTRIBUTED TO THE ANTIPSYCHOTIC DRUG AS OPPOSED TO SOME
CHARACTERISTIC(S) OF THE PATIENTS IS NOT CLEAR. FAZACLO®
(clozapine, USP) IS NOT APPROVED FOR THE
TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (SEE WARNINGS.)
FazaClo (clozapine) PI

